Open Access Open Access  Restricted Access Subscription Access

REVIEW ON APLASTIC ANEMIA

Ms. Shrutika Krishnadas Patil, Ms. Harshada Kailas Patil, Ms. Hemangi Somnath Chaudhari, Ms. Pallavi Bhilaji Jire

Abstract


Aplastic anemia is an ancient disease. The first patient was recorded by the young Paul Ehrlich in 1885; Vaquez coined the term "anemia aplastique" in 1904; and Cabot and other pathologists detailed its clinical symptoms in the beginning of the 20th century. In the current period, an almost consistently deadly prognosis, mostly for young people with abrupt acute pancytopenia, has been reversed, with the introduction of viable treatments for almost all patients. In the research laboratory, understanding of pathophysiology has guided therapy development. Marrow failure syndromes have been linked to viral infections and environmental pollutants, inherited and acquired genetic abnormalities, early leukemogenic events, and normal aging hematopoiesis.


Full Text:

PDF

References


Passweg JR, Marsh JC. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hema-tology Am Soc Hematol Educ Program. 2010;2010:36-42.

Valdez JM, Scheinberg P, Nunez O, Wu CO, Young NS, Walsh TJ. Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011;52(6):726–35.

Kaufman DW, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia. Oxford; New York: 1991.

Issaragrisil S, Kaufman D, Anderson T, Chansung K, Leaverton P, Shapiro S, Young NS, The Aplastic Anemia Study G The epidemiology of aplastic anemia in Thailand. Blood. 2006;107:1299–1307. [PMC free article] [PubMed] [Google Scholar]This large epidemiologic study enrolled more than 500 patients and 2,000 case controls; an accurate incidence rate was obtained, and there were environmental associations with the disease that were familiar (chemicals and drugs) and others that were unexpected (water source, animal exposure).

Hamerschlak N, Maluf E, Pasquini R, Eluf-Neto J, Moreira FR, Cavalcanti AB, Okano ÍR, Falcão RP, Pita MT, Loggetto SR, et al. Incidence of aplastic anemia and agranulocytosis in Latin America: the LATIN study. Sao Paulo Medical Journal. 2005;123:101–104.

Young NS, Young NS, Alter BP. Drugs and chemicals. In: Saunders WB, editor. Aplastic Anemia, Acquired and Inherited. 1994. pp. 100–132.

Gerson WT, Fine DG, Spielberg SP, Sensenbrenner LL. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood. 1983;61:889–893.

Sutton JF, Stacey M, Kearsey SE, Reig TS, Young NS, Liu JM. Increased risk for aplastic anemia and myelodysplastic syndrome in individuals lacking GSTT1 gene. Pediatric Blood Cancer. 2004;42:122–126.

Dufour C, Syahn J, Bacigalupo A, Longoni D, Varotto S, Iori AP, Bagnasco F, Locasciulli A, Menna G, Ramenghi U, et al. Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients. Haematologica. 2005;90:1027–1031.

Lu J, Basu A, Melenhorst J, Young NS, Brown KE. Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood. 2004;103:4588–4593.


Refbacks

  • There are currently no refbacks.